Maxim Group set a $14.00 price target on Galmed Pharmaceuticals (NASDAQ:GLMD) in a report published on Tuesday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
Several other equities analysts have also recently weighed in on GLMD. ValuEngine cut shares of Galmed Pharmaceuticals from a sell rating to a strong sell rating in a research note on Wednesday, March 28th. Zacks Investment Research cut shares of Galmed Pharmaceuticals from a buy rating to a hold rating in a research note on Thursday, January 11th. Finally, HC Wainwright raised their target price on shares of Galmed Pharmaceuticals from $18.00 to $24.00 and gave the company a buy rating in a research note on Monday, February 12th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The stock has an average rating of Buy and an average price target of $20.40.
Shares of GLMD traded down $0.07 during mid-day trading on Tuesday, hitting $6.00. 10,036 shares of the company’s stock were exchanged, compared to its average volume of 83,230. Galmed Pharmaceuticals has a 52 week low of $3.61 and a 52 week high of $12.22.
Several large investors have recently added to or reduced their stakes in GLMD. Deutsche Bank AG bought a new position in shares of Galmed Pharmaceuticals in the fourth quarter valued at $246,000. Renaissance Technologies LLC bought a new position in shares of Galmed Pharmaceuticals in the fourth quarter valued at $345,000. J. Goldman & Co LP bought a new position in shares of Galmed Pharmaceuticals in the fourth quarter valued at $569,000. Sphera Funds Management LTD. bought a new position in shares of Galmed Pharmaceuticals in the fourth quarter valued at $2,164,000. Finally, Park West Asset Management LLC grew its stake in shares of Galmed Pharmaceuticals by 4.4% in the fourth quarter. Park West Asset Management LLC now owns 292,847 shares of the biopharmaceutical company’s stock valued at $2,679,000 after buying an additional 12,347 shares in the last quarter. 18.86% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “Galmed Pharmaceuticals (GLMD) PT Set at $14.00 by Maxim Group” was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/3335701/galmed-pharmaceuticals-glmd-pt-set-at-14-00-by-maxim-group.html.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.